Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 10, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Hypofractionation for clinically localized prostate cancer.

Alvin R Cabrera1, W Robert Lee

  • 1Department of Radiation Oncology, Duke Cancer Institute, Durham, NC 27710, USA. alvin.cabrera@duke.edu

Seminars in Radiation Oncology
|June 15, 2013
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correlation of Biochemical Recurrence With Adverse Late Toxic Events Following Prostate Radiation Therapy (COBALT Study): An Individual Patient Data Meta-Analysis of 7 Randomized Trials.

International journal of radiation oncology, biology, physics·2026
Same author

The Radiation Oncology Match in 2025: A New Steady-State?

Practical radiation oncology·2025
Same author

Hypofractionated radiotherapy for prostate cancer (HYDRA): an individual patient data meta-analysis of randomised trials in the MARCAP consortium.

The Lancet. Oncology·2025
Same author

The interplay between acute and late toxicity among patients receiving prostate radiotherapy: an individual patient data meta-analysis of six randomised trials.

The Lancet. Oncology·2025
Same author

In Reply to Fastner et al.

Practical radiation oncology·2025
Same author

In Reply to Kaidar-Person et al.

Practical radiation oncology·2024
Same journal

Integrative Medicine for Breast Cancer Survivors.

Seminars in radiation oncology·2026
Same journal

Integrative Oncology Approaches for Gastrointestinal Symptoms and Risk Reduction in Patients With Digestive Tract Cancers.

Seminars in radiation oncology·2026
Same journal

Integrative Oncology and Radiation Therapy: An Essential Evolution.

Seminars in radiation oncology·2026
Same journal

Clinical Trials of Integrative Oncology Interventions for Radiation Therapy: Emerging Evidence and Opportunities.

Seminars in radiation oncology·2026
Same journal

Nonpharmacologic Approaches for Pain Management in Patients With Cancer Treated With Radiation Therapy.

Seminars in radiation oncology·2026
Same journal

Integrative Therapies for Radiation-Related Toxicities in Hematological Malignancies.

Seminars in radiation oncology·2026
See all related articles

Hypofractionation for prostate cancer shows inconsistent results in moderate doses and limited evidence for extreme doses. Further trials are needed to clarify its role in cancer therapy.

Area of Science:

  • Oncology
  • Radiation Oncology
  • Clinical Urology

Background:

  • Hypofractionation, involving higher radiation doses per fraction, is an evolving treatment strategy for prostate cancer.
  • Moderate hypofractionation uses 2.4-4 Gy per fraction, while extreme hypofractionation uses 6.5-10 Gy per fraction.

Purpose of the Study:

  • To review the clinical evidence for hypofractionation in prostate cancer, specifically from prospective trials.
  • To assess the current data on moderate and extreme hypofractionation efficacy and safety.

Main Methods:

  • Review of five randomized controlled trials (RCTs) evaluating moderate hypofractionation in over 1500 men.
  • Analysis of prospective single-arm studies for extreme hypofractionation.
  • Evaluation of follow-up durations and sample sizes in existing studies.

More Related Videos

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

Focal Laser Ablation of Prostate Cancer: An Office Procedure
11:07

Focal Laser Ablation of Prostate Cancer: An Office Procedure

Published on: March 30, 2021

Related Experiment Videos

Last Updated: May 10, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

Focal Laser Ablation of Prostate Cancer: An Office Procedure
11:07

Focal Laser Ablation of Prostate Cancer: An Office Procedure

Published on: March 30, 2021

Main Results:

  • Inconsistent results were observed across RCTs for moderate hypofractionation.
  • No RCTs directly compare extreme hypofractionation with conventional fractionation.
  • Prospective studies of extreme hypofractionation show promise, but have small sample sizes and limited follow-up.

Conclusions:

  • The clinical evidence for moderate hypofractionation in prostate cancer is currently inconsistent.
  • Robust data on extreme hypofractionation is lacking, hindering definitive conclusions on its efficacy and safety.
  • Upcoming large noninferiority and randomized trials are expected to provide clearer guidance on hypofractionation's role.